Merck's Nemtabrutinib Phase 3 Trial Aims to Challenge First-Line BTK Inhibitors in CLL
Clinical Design and Development Objectives
Merck & Co. (MRK)'s BELLWAVE-011 is a global, randomized, open-label Phase 3 trial enrolling approximately 1,200 patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are treatment-naive. Nemtabrutinib (MK-1026, ARQ 531), an investigational, oral, reversible, non-covalent Bruton's tyrosine kinase (BTK) inhibitor, targets both wild-type BTK and BTK mutations associated with resistance. The trial directly compares nemtabrutinib to ibrutinib or acalabrutinib, as selected by investigators, making it more focused on demonstrating the potential for first-line treatment entry rather than simply confirming efficacy.
Primary and Secondary Endpoints
The co-primary endpoints are objective response rate (ORR) and progression-free survival (PFS), as assessed by blinded independent central review (BICR) according to iwCLL 2018 criteria. The design, which aims to demonstrate superiority in PFS after achieving non-inferiority in ORR, is intended to provide more durable disease control while maintaining initial tumor reduction. Combining open-label treatment with central review helps reduce potential assessment bias and increases the reliability of the data for regulatory submissions.
Competitive Landscape and Regulatory Considerations
Ibrutinib, co-commercialized by AbbVie (ABBV) and Johnson & Johnson (JNJ), is a covalent BTK inhibitor that received FDA approval for CLL on July 28, 2014, and AstraZeneca (AZN)'s Calquence received CLL/SLL approval on November 21, 2019. The competitive landscape also includes BeOne Medicines' (ONC) zanubrutinib (Brukinsa), AbbVie's venetoclax-based fixed-duration therapy, and Eli Lilly (LLY)'s non-covalent BTK inhibitor pirtobrutinib (Jaypirca). Jaypirca received accelerated approval in December 2023 for heavily pre-treated CLL/SLL and, on December 3, 2025, received full FDA approval for patients after treatment with covalent BTK inhibitors, raising the bar for nemtabrutinib's differentiation within the class.
Market Potential and Investment Implications
The global CLL treatment market is projected to expand from USD 7.0 billion in 2024 to USD 12.96 billion in 2032, according to Verified Market Research, and AbbVie reported global net revenues of USD 2.869 billion for ibrutinib in 2025. If nemtabrutinib demonstrates superior PFS and manageable cardiovascular and bleeding safety in the first-line setting, Merck can establish a foundation for its hematologic oncology franchise, reducing its reliance on Keytruda. Conversely, if the large, long-term trial shows limited differentiation, it will be difficult to change the established prescribing patterns of Brukinsa, Calquence, and fixed-duration venetoclax combinations, making an observational approach appropriate until the clinical results are announced.
A successful Phase 3 trial involving approximately 1,200 patients will allow Merck & Co. (MRK) to secure a first-line treatment entry in the global CLL market, which is valued at USD 7.0 billion in 2024. The direct comparison to marketed BTK inhibitors, ibrutinib and Calquence, means that PFS superiority, as well as atrial fibrillation, bleeding, and infection safety, will be key factors in adoption, given their established prescribing experience and long-term follow-up data. For researchers, this is a critical trial to determine whether non-covalent BTK inhibition can delay the development of resistance even in treatment-naive patients. In the short term, the trial's progress and interim safety signals will impact MRK's pipeline value, and in the medium to long term, it could reshape the competitive landscape, including Brukinsa and fixed-duration venetoclax therapy. While Jaypirca, which received full FDA approval in 2025, has established a regulatory precedent for non-covalent inhibitors, nemtabrutinib will need to demonstrate separate first-line differentiation in its Phase 3 trial.
Source: ClinicalTrials.gov (api_ct)